Panel discussion – Biosimilar – between original and generic – law, chemistry, politics
What counts for cost reimbursement of Biosimilars?
This question shall be discussed at GEISTWERT’s panel discussion
„Biosimilar – between original and generic – law, chemistry, politics “
On the panel:
Dr. Beatrix Metzner, Director Global CMC Strategy and Tech RA at Boehringer Ingelheim, Ingelheim am Rhein
- Responsible for CMC regulatory strategy for Biosimilars
Dr. Markus Fido, CEO at VelaLabs GmbH, Vienna
- PhD in biochemistry/cell biology and specialist for product development Biosimilars, Biopharmaceuticals, Biologics
Dr. Wolfgang Andiel, Head BU Hospital, Biopharma & Oncology Injectables at Sandoz GmbH, Vienna
- Represents the Austrian Association for Biosimilars, President of the Austrian Association for Generics (Generikaverband)
Dr. Eva Pasching, Franchise Head Hematology, Baxalta Österreich GmbH. Now part of Shire
- Has launched several biosimilars
presented by Rainer Schultes, Partner at GEISTWERT Rechtsanwälte
When: 17. 10. 2016, 3 to 5 pm – followed by networking and finger food
Where: GEISTWERT Rechtsanwälte, Linke Wienzeile 4,1060 Vienna
registration: office@geistwert.at